Tirzepatide is a dual GIP and GLP-1 receptor agonist developed to target multiple metabolic pathways simultaneously. Its unique mechanism makes it a cornerstone compound in modern metabolic and glycemic control protocols.

Each unit is protected with anti-counterfeit measures and produced in accordance with rigorous quality standards, suitable for clinical, research, and advanced wellness applications.

Key features

• Dual GIP / GLP-1 receptor agonist
• Controlled pen delivery
• Secure, authenticated packaging
• Professional-grade formulation